TABLE 1.
Screening and select baseline characteristics of participants who completed the study and those lost to follow-up
| Completed (n = 15) | Lost to follow-up (n = 8) | |
|---|---|---|
| Age, y | 53 ± 2 (42–65) | 51 ± 2 (43–64) |
| Years postmenopausal (women only) | 5 ± 1 (1–8) | 10 ± 2 (1–16) |
| Sex, M:F (n) | 7:8 | 2:6 |
| BMI, kg/m2 | 29.8 ± 0.9 (26.2–36.4) | 30.0 ± 1.5 (25.2–36.9) |
| Waist-to-hip ratio | 0.86 ± 0.02 (0.76–1.00) | 0.86 ± 0.02 (0.78–0.93) |
| Total cholesterol, mg/dL | 202 ± 11 (100–278) | 219 ± 9 (190–271) |
| HDL, mg/dL | 59 ± 4 (17–85) | 55 ± 3 (42–69) |
| LDL, mg/dL | 131 ± 0 (86–181) | 144 ± 10 (116–190) |
| Triglycerides, mg/dL | 112 ± 16 (45–249) | 121 ± 21 (45–222) |
| HDL:LDL ratio | 0.48 ± 0.05 (0.27–0.86) | 0.38 ± 0.04 (0.24–0.58) |
| Hemoglobin A1c, % | 5.3 ± 0.1 (5.0–6.0) | 5.4 ± 0.1 (5.0–5.8) |
| HOMA-IR | 0.79 ± 0.11 (0.21–1.52) | — |
| SBP, mmHg | 121 ± 3 (97–136) | 115 ± 3 (103–123) |
| DBP, mmHg | 78 ± 2 (62–89) | 80 ± 3 (66–88) |
| RHI* | 1.74 ± 0.09 (1.26–2.38) | 2.17 ± 0.26 (1.27–3.79) |
| PWV, m/s | 7.2 ± 0.4 (4.6–10.0) | 6.9 ± 0.25 (5.4–7.6) |
Values are mean ± SEM (ranges).
*
RHI and HOMA-IR were measured at the baseline visit (HOMA-IR not calculated for those who dropped the study due to not analyzing blood biomarkers at baseline visit). DBP, diastolic blood pressure; PWV, pulse wave velocity; RHI, reactive hyperemia index; SBP, systolic blood pressure; WC, waist circumference.